Healthcare

Cannabis Testing Market Demands and Gross Margin 2026

Press Release

Cannabis testing involves quantification of major chemical compound and active ingredient in the given specimen of cannabis. Cannabinoids and terpene are major active ingredient that has medicinal potency. Depending on the concentration of the chemical active ingredient, the potency of the sample representing huge quantity of cannabis is decided. Cannabis testing is performed with the help of analytical instruments such as liquid chromatography, gas chromatography etc. Commercial labs offers dedicated cannabis testing services in developed region. Increasing number of the medicinal usage is propelling demand for commercial manufacturing of cannabis. However, government authorities demands quality testing of the cannabis before using them for recreational and medicinal purpose.

Request a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/170

Market Dynamics

Cannabis testing products and services market is witnessing significant growth with increased government approval and loosening regulatory stringent ness over use of cannabis for commercial and recreational purpose. For instance, in February 2016, the Australian government amended the Narcotics Drugs Act 1967, to allow cultivation of cannabis for medicinal or scientific purposes under a national licensing scheme, which is expected to favor the growth of the commercial manufacturing of cannabis plant in the region, which in turn would also drive growth of the cannabis testing market. Furthermore, the Australian government in January 2018, announced that it would allow medicinal cannabis exports, which is expected to provide growth opportunities for domestic manufacturers. Increasing number of laboratories offering cannabis testing is expected to further drive the market growth.

Legalization of cannabis for medicinal and recreational activity to drive growth of the cannabis testing market

Increasing approval of medicinal cannabis products along with extensive research and development activities in the medical cannabis market are expected to support growth of the cannabis testing market.

Cannabis testing market is projected to witness positive growth during the forecast period, owing to the requirement of desired active ingredient detection and undesired trace elements (mycotoxins and trace metals) before utilizing cannabis product for medicinal and recreational purpose. Increased trend of using cannabis for recreational purpose would be another major impetus for simultaneous rise in cannabis testing market.

Key players operating in the cannabis testing market include Shimadzu Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Millipore Sigma, AB SCIEX LLC, Cannabix Technologies, Inc., Waters Corporation, Steep Hill Labs, Inc., CannaSafe Analytics, Accelerated Technology Laboratories, Inc., LabLynx, Inc., SC Laboratories Inc., GenTech Scientific, Pharm Labs, LLC, and Digipath Labs, Inc.

Ask For The PDF Sample : https://www.coherentmarketinsights.com/insight/request-sample/170

Detailed Segmentation:

  • Global Cannabis Testing Market, By Product and Service Type:
    • Product type
      • Analytical Instruments
        • Chromatography Instruments
          • Liquid Chromatography
          • Gas Chromatography
          • Others
        • Spectroscopy Instruments
          • Mass Spectroscopy
          • Atomic Spectroscopy
      • Consumables
      • Breathe Analyzer
    • Service Type
      • Potency Testing
      • Terpene Testing
      • Pesticide Testing
      • Residual Solvent
      • Heavy Metal Testing
      • Mycotoxin and Microbial Testing
      • Others
  • Global Cannabis Testing Market, By End Users:
    • Testing Laboratories
    • Drug Manufacturer
    • Research Institutes

ncreased approval for cannabis-based drugs and new product launches for cannabis testing are expected to propel growth of the cannabis testing market

Various cannabis manufacturer across globe are focused on introducing the cannabis products to target various disease, which in turn is expected to promote application of cannabis testing instruments, as this products need to be approved from the health regulatory bodies for their efficacy and purity. For instance, in May 2018, the U.S Food and Drug Administration (FDA) approved the medication, called Epidiolex manufactured by GW Pharmaceuticals to treat two rare forms of epilepsy caused by Lennox-Gastaut and Dravet syndromes in patients two years and older.

In July 2016, Insys Therapeutics, Inc. received U.S.FDA approval for dronabinol oral solution- Syndros, which is an orally administered liquid formulation of cannabinoid dronabinol. The Syndros is indicated for treatment of anorexia associated with weight loss among patients suffering from AIDS and patients suffering from cancer chemotherapy-induced nausea and vomiting.

This post was originally published on Trading Herald

RSS news